Halozyme Therapeutics HALO
NASDAQ HALO
$101.68 -1.30 (-1.26%)
At close: Nov 11, 2026 · 4:00 PM EST

Halozyme Therapeutics (HALO) Return on Equity [ROE] (2009 - 2026)

Updated

Halozyme Therapeutics' Return on Equity [ROE] was 227.75% in Q2 2026, up 90.99 percentage points from 136.75% a year earlier but down 32.13 percentage points from the prior quarter.

Analysis

Halozyme Therapeutics (HALO) Return on Equity [ROE] (2009 - 2026) Analysis & Trends

For FY2025, Return on Equity [ROE] at Halozyme Therapeutics came in at 153.59%, down 44.83 percentage points from FY2024.

  • Return on Equity [ROE] shows a five-year change of +47.27 percentage points (FY2020 to FY2025).
  • In earlier years, Return on Equity [ROE] was 198.42% in FY2024 (-23.65 pp), 222.07% in FY2023 (+111.85 pp), 110.23% in FY2022 (-121.22 pp) and 231.44% in FY2021 (+125.12 pp).
  • Quarterly Return on Equity [ROE] has moved between 105.77% (Q3 2024) and 259.88% (Q1 2026) over five years.
  • Compared with a year earlier, Return on Equity [ROE] has increased for four straight quarters, with an average year-over-year change of +7.57 percentage points over the last eight quarters.
  • The best year-over-year quarter for Return on Equity [ROE] over five years was Q3 2021 (a gain of 182.78 percentage points); the worst was Q1 2025 (a drop of 128.99 percentage points).
  • Per Business Quant data, HALO's Return on Equity [ROE] in the three quarters before Q2 2026 was 259.88% (Q1 2026), 114.66% (Q4 2025) and 142.35% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 74.39%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 19.33%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 5.63%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 21.60%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 72.13%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -31.17%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 4.66%
10 Halozyme Therapeutics 11.73 Bn 9.97 Bn 410.50 Mn 1,099.31%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 1,099.31%
Jun 30, 2026 227.75%
Mar 31, 2026 259.88%
Dec 31, 2025 114.66%
Sep 30, 2025 142.35%
Jun 30, 2025 136.75%
Mar 31, 2025 114.73%
Dec 31, 2024 108.78%
Sep 30, 2024 105.77%
Jun 30, 2024 144.38%
Mar 31, 2024 243.72%
Dec 31, 2023 169.13%
Sep 30, 2023 126.89%
Jun 30, 2023 215.51%
Mar 31, 2023 154.16%
Dec 31, 2022 151.53%
Sep 30, 2022 108.26%
Jun 30, 2022 132.32%
Mar 31, 2022 190.25%
Dec 31, 2021 168.28%
API Access

Halozyme Therapeutics Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=HALO&period=max&api_key=YOUR_API_KEY